Nubratori RX, began just after the enactment by Congress, of the Drug Quality and Security Act of 2013. Nubratori RX spent its first four years in research and development, testing, and validating potential new products as requested by healthcare providers. 2017 brought the launch of Nubratori RX’s first production run. To date, Nubratori RX has produced over 250,000 units of medications and counting, with zero adverse reports. Emerging successfully from the COVID-19 pandemic, Nubratori RX is looking to double its existing business and continues to proudly serve patients, healthcare providers, pharmacies, hospitals and clinics.
Nubratori RX, under its FDA Registration for Outsourcing Facilities, compounds and manufactures cGMP sterile and non-sterile medications requested by providers when they have made a determination there is a clinically significant difference to meet the patient's needs over other commercially available products on the market.
If you are a hospital administrator, pharmacist, healthcare provider or physician and would like to find out more, please contact us.
Meet the Team
COO and Director of Regulatory Affairs
BioScience Regulatory Affairs
Director of Research and
New Product Development
Quality Control Supervisor Supervising Pharmacist
Exercise Biology B.S.
Certified Vocational Nurse
Director of Quality Assurance
National Product Advocate
Director of Licensing
381 Van Ness Ave Suite 1507, 1508, Torrance, CA 90501